Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

MRI Findings Suggestive of Herpes Simplex Encephalitis in Patients with Anti-NMDA Receptor Encephalitis.

Scheel M, Finke C.

AJNR Am J Neuroradiol. 2018 Sep 13. doi: 10.3174/ajnr.A5788. [Epub ahead of print] No abstract available.

PMID:
30213819
2.

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms.

Patnaik MM, Lasho T, Howard M, Finke C, Ketterling RL, Al-Kali A, Pardanani A, Droin N, Gangat N, Tefferi A, Solary E.

Blood Cancer J. 2018 Aug 22;8(9):82. doi: 10.1038/s41408-018-0120-5. No abstract available.

3.

Anti-ARHGAP26 Autoantibodies Are Associated With Isolated Cognitive Impairment.

Bartels F, Prüss H, Finke C.

Front Neurol. 2018 Aug 10;9:656. doi: 10.3389/fneur.2018.00656. eCollection 2018.

4.

Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.

Szuber N, Vallapureddy RR, Penna D, Lasho TL, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Aug 29. doi: 10.1002/ajh.25270. [Epub ahead of print]

PMID:
30157297
5.

Mutations and karyotype predict treatment response in myelodysplastic syndromes.

Idossa D, Lasho T, Finke C, Ketterling R, Patnaik M, Pardanani A, Gangat N, Tefferi A.

Am J Hematol. 2018 Aug 28. doi: 10.1002/ajh.25267. [Epub ahead of print]

PMID:
30152885
6.

Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of 39 patients.

Pophali P, Horna P, Lasho TL, Finke CM, Ketterling RP, Gangat N, Nagorney D, Tefferi A, Patnaik MM.

Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25246. [Epub ahead of print]

PMID:
30105755
7.

Selective vs stepwise removal of deep carious lesions in primary molars: 12-Months results of a randomized controlled pilot trial.

Elhennawy K, Finke C, Paris S, Reda S, Jost-Brinkmann PG, Schwendicke F.

J Dent. 2018 Oct;77:72-77. doi: 10.1016/j.jdent.2018.07.011. Epub 2018 Jul 17.

PMID:
30025748
8.

Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis.

Mudireddy M, Gangat N, Lasho TL, Finke C, Hanson CA, Ketterling RP, Ashrani AA, Pardanani A, Nagorney DM, Tefferi A.

Am J Hematol. 2018 Jul 7. doi: 10.1002/ajh.25203. [Epub ahead of print] No abstract available.

PMID:
29981287
9.

Beyond the limbic system: disruption and functional compensation of large-scale brain networks in patients with anti-LGI1 encephalitis.

Heine J, Prüss H, Kopp UA, Wegner F, Then Bergh F, Münte T, Wandinger KP, Paul F, Bartsch T, Finke C.

J Neurol Neurosurg Psychiatry. 2018 Jun 9. pii: jnnp-2017-317780. doi: 10.1136/jnnp-2017-317780. [Epub ahead of print]

PMID:
29886429
10.

Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information.

Tefferi A, Gangat N, Mudireddy M, Lasho TL, Finke C, Begna KH, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, He R, Viswanatha D, Hanson CA, Ketterling RP, Tang JL, Chou WC, Lin CC, Tsai CH, Tien HF, Hou HA.

Mayo Clin Proc. 2018 Jun 14. pii: S0025-6196(18)30312-4. doi: 10.1016/j.mayocp.2018.04.013. [Epub ahead of print]

PMID:
29866419
11.

A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.

Patnaik MM, Rangit Vallapureddy, Lasho TL, Hoversten KP, Finke CM, Ketterling RP, Hanson CA, Gangat N, Tefferi A, Pardanani A.

Leukemia. 2018 Aug;32(8):1850-1856. doi: 10.1038/s41375-018-0121-1. Epub 2018 Apr 2. No abstract available.

PMID:
29712989
12.

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.

Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema Gangat, Pardanani A, Vannucchi AM.

Leukemia. 2018 Jul;32(7):1631-1642. doi: 10.1038/s41375-018-0107-z. Epub 2018 Mar 23.

13.

Diagnosing MRI-negative autoimmune diseases.

Finke C.

Neurol Neuroimmunol Neuroinflamm. 2018 Apr 2;5(3):e457. doi: 10.1212/NXI.0000000000000457. eCollection 2018 May. No abstract available.

14.

Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates.

Hoversten K, Vallapureddy R, Lasho T, Finke C, Ketterling R, Hanson C, Gangat N, Tefferi A, Patnaik MM.

Leuk Lymphoma. 2018 Mar 27:1-4. doi: 10.1080/10428194.2018.1452212. [Epub ahead of print] No abstract available.

PMID:
29582697
15.

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions.

Tefferi A, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Leukemia. 2018 Feb 27. doi: 10.1038/s41375-018-0078-0. [Epub ahead of print] No abstract available.

PMID:
29535431
16.

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms.

Lasho TL, Vallapureddy R, Finke CM, Mangaonkar A, Gangat N, Ketterling R, Tefferi A, Patnaik MM.

Blood Cancer J. 2018 Mar 12;8(3):32. doi: 10.1038/s41408-018-0057-8. No abstract available.

17.

U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates.

Tefferi A, Mudireddy M, Finke CM, Nicolosi M, Lasho TL, Hanson CA, Patnaik MM, Pardanani A, Gangat N.

Am J Hematol. 2018 Jun;93(6):E146-E148. doi: 10.1002/ajh.25084. Epub 2018 Apr 6. No abstract available.

PMID:
29516544
18.

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.

Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Szuber N, Begna KH, Patnaik MM, Gangat N, Pardanani A, Tefferi A.

Blood Adv. 2018 Feb 27;2(4):370-380. doi: 10.1182/bloodadvances.2018015875.

19.

Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex.

Jaeger S, Paul F, Scheel M, Brandt A, Heine J, Pach D, Witt CM, Bellmann-Strobl J, Finke C.

Mult Scler. 2018 Feb 1:1352458518758911. doi: 10.1177/1352458518758911. [Epub ahead of print]

20.

CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival.

Szuber N, Finke CM, Lasho TL, Elliott MA, Hanson CA, Pardanani A, Tefferi A.

Blood Cancer J. 2018 Feb 15;8(2):21. doi: 10.1038/s41408-018-0058-7. No abstract available.

21.

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts.

Mangaonkar AA, Lasho TL, Finke CM, Gangat N, Al-Kali A, Elliott MA, Begna KH, Alkhateeb H, Wolanskyj-Spinner AP, Hanson CA, Ketterling RP, Hogan WJ, Pardanani A, Litzow MR, Tefferi A, Patnaik MM.

Blood Cancer J. 2018 Feb 12;8(2):18. doi: 10.1038/s41408-018-0051-1. No abstract available.

22.

Mayo CALR mutation type classification guide using alpha helix propensity.

Lasho TL, Finke CM, Tischer A, Pardanani A, Tefferi A.

Am J Hematol. 2018 May;93(5):E128-E129. doi: 10.1002/ajh.25065. Epub 2018 Feb 24. No abstract available.

PMID:
29424450
23.

Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model.

Gangat N, Mudireddy M, Lasho TL, Finke CM, Nicolosi M, Szuber N, Patnaik MM, Pardanani A, Hanson CA, Ketterling RP, Tefferi A.

Am J Hematol. 2018 May;93(5):691-697. doi: 10.1002/ajh.25064. Epub 2018 Feb 24.

PMID:
29417633
24.

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental.

Patnaik MM, Vallapureddy R, Lasho TL, Hoversten KP, Finke CM, Ketterling R, Hanson C, Gangat N, Tefferi A.

Blood Cancer J. 2018 Jan 22;8(1):12. doi: 10.1038/s41408-017-0045-4. No abstract available.

25.

Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis.

Backner Y, Kuchling J, Massarwa S, Oberwahrenbrock T, Finke C, Bellmann-Strobl J, Ruprecht K, Brandt AU, Zimmermann H, Raz N, Paul F, Levin N.

JAMA Neurol. 2018 Mar 1;75(3):287-295. doi: 10.1001/jamaneurol.2017.3880.

PMID:
29297053
26.

Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization.

Finke C, Zimmermann H, Pache F, Oertel FC, Chavarro VS, Kramarenko Y, Bellmann-Strobl J, Ruprecht K, Brandt AU, Paul F.

JAMA Neurol. 2018 Mar 1;75(3):296-303. doi: 10.1001/jamaneurol.2017.3890.

PMID:
29297041
27.

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients.

Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Tefferi A.

Blood Cancer J. 2017 Dec 27;7(12):662. doi: 10.1038/s41408-017-0035-6.

28.

Pursuing functional connectivity in NMDAR1 autoantibody carriers - Authors' reply.

Peer M, Prüss H, Ben-Dayan I, Paul F, Arzy S, Finke C.

Lancet Psychiatry. 2018 Jan;5(1):22. doi: 10.1016/S2215-0366(17)30488-1. No abstract available.

PMID:
29277209
29.

JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease.

Tefferi A, Lavu S, Mudireddy M, Lasho TL, Finke CM, Gangat N, Pardanani A, Hanson CA, Mannarelli C, Guglielmelli P, Vannucchi AM.

Am J Hematol. 2018 Aug;93(4):E93-E96. doi: 10.1002/ajh.25017. No abstract available.

PMID:
29274140
30.

Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q).

Tefferi A, Idossa D, Lasho TL, Mudireddy M, Finke C, Shah S, Nicolosi M, Patnaik MM, Pardanani A, Gangat N, Hanson CA, Ketterling RP.

Blood Cancer J. 2017 Dec 18;7(12):658. doi: 10.1038/s41408-017-0017-8. No abstract available.

31.

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.

Tefferi A, Nicolosi M, Mudireddy M, Szuber N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Mannarelli C, Fanelli T, Guglielmelli P, Vannucchi AM.

Am J Hematol. 2018 Mar;93(3):348-355. doi: 10.1002/ajh.24978. Epub 2017 Dec 18.

PMID:
29164670
32.

Superficial white matter damage in anti-NMDA receptor encephalitis.

Phillips OR, Joshi SH, Narr KL, Shattuck DW, Singh M, Di Paola M, Ploner CJ, Prüss H, Paul F, Finke C.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):518-525. doi: 10.1136/jnnp-2017-316822. Epub 2017 Nov 3.

PMID:
29101253
33.

Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis.

Tefferi A, Lasho TL, Finke C, Gangat N, Hanson CA, Ketterling RP, Pardanani A.

Leukemia. 2018 Mar;32(3):837-839. doi: 10.1038/leu.2017.318. Epub 2017 Nov 1. No abstract available.

PMID:
29089644
34.

Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.

Patnaik MM, Vallapureddy R, Yalniz FF, Hanson CA, Ketterling RP, Lasho TL, Finke C, Al-Kali A, Gangat N, Tefferi A.

Am J Hematol. 2018 Jan;93(1):65-73. doi: 10.1002/ajh.24939. Epub 2017 Nov 3.

PMID:
29023992
35.

Functional connectivity of large-scale brain networks in patients with anti-NMDA receptor encephalitis: an observational study.

Peer M, Prüss H, Ben-Dayan I, Paul F, Arzy S, Finke C.

Lancet Psychiatry. 2017 Oct;4(10):768-774. doi: 10.1016/S2215-0366(17)30330-9. Epub 2017 Sep 4.

PMID:
28882707
36.

Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.

Tefferi A, Lasho TL, Patnaik MM, Saeed L, Mudireddy M, Idossa D, Finke C, Ketterling RP, Pardanani A, Gangat N.

Am J Hematol. 2017 Dec;92(12):1311-1317. doi: 10.1002/ajh.24901. Epub 2017 Oct 20.

PMID:
28875545
37.

Oral manifestations, dental management, and a rare homozygous mutation of the PRDM12 gene in a boy with hereditary sensory and autonomic neuropathy type VIII: a case report and review of the literature.

Elhennawy K, Reda S, Finke C, Graul-Neumann L, Jost-Brinkmann PG, Bartzela T.

J Med Case Rep. 2017 Aug 15;11(1):233. doi: 10.1186/s13256-017-1387-z. Review.

38.

High prevalence of neuronal surface autoantibodies associated with cognitive deficits in cancer patients.

Finke C, Bartels F, Lütt A, Prüss H, Harms L.

J Neurol. 2017 Sep;264(9):1968-1977. doi: 10.1007/s00415-017-8582-0. Epub 2017 Aug 7.

PMID:
28785798
39.

Memory integration in humans with hippocampal lesions.

Pajkert A, Finke C, Shing YL, Hoffmann M, Sommer W, Heekeren HR, Ploner CJ.

Hippocampus. 2017 Dec;27(12):1230-1238. doi: 10.1002/hipo.22766. Epub 2017 Aug 9.

PMID:
28768057
40.

Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance.

Vallapureddy R, Lasho TL, Hoversten K, Finke CM, Ketterling R, Hanson C, Gangat N, Tefferi A, Patnaik MM.

Am J Hematol. 2017 Oct;92(10):E614-E618. doi: 10.1002/ajh.24861. Epub 2017 Jul 29. No abstract available.

PMID:
28707414
41.

Cognitive outcomes following anti-N-methyl-D-aspartate receptor encephalitis: A systematic review.

McKeon GL, Robinson GA, Ryan AE, Blum S, Gillis D, Finke C, Scott JG.

J Clin Exp Neuropsychol. 2018 Apr;40(3):234-252. doi: 10.1080/13803395.2017.1329408. Epub 2017 Jun 6.

PMID:
28585453
42.

Monocytosis in polycythemia vera: Clinical and molecular correlates.

Barraco D, Cerquozzi S, Gangat N, Patnaik MM, Lasho T, Finke C, Hanson CA, Ketterling RP, Pardanani A, Tefferi A.

Am J Hematol. 2017 Jul;92(7):640-645. doi: 10.1002/ajh.24740. Epub 2017 May 26.

43.

Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.

Patnaik MM, Barraco D, Lasho TL, Finke CM, Reichard K, Hoversten KP, Ketterling RP, Gangat N, Tefferi A.

Am J Hematol. 2017 Jun;92(6):542-548. doi: 10.1002/ajh.24722. Epub 2017 Apr 29.

44.

Targeted deep sequencing in primary myelofibrosis.

Tefferi A, Lasho TL, Finke CM, Elala Y, Hanson CA, Ketterling RP, Gangat N, Pardanani A.

Blood Adv. 2016 Nov 30;1(2):105-111. doi: 10.1182/bloodadvances.2016000208. eCollection 2016 Dec 13.

45.

Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies.

Finke C, Prüss H, Heine J, Reuter S, Kopp UA, Wegner F, Then Bergh F, Koch S, Jansen O, Münte T, Deuschl G, Ruprecht K, Stöcker W, Wandinger KP, Paul F, Bartsch T.

JAMA Neurol. 2017 Jan 1;74(1):50-59. doi: 10.1001/jamaneurol.2016.4226.

PMID:
27893017
46.

Targeted deep sequencing in polycythemia vera and essential thrombocythemia.

Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, Pacilli A, Hanson CA, Pancrazzi A, Ketterling RP, Mannarelli C, Barraco D, Fanelli T, Pardanani A, Gangat N, Vannucchi AM.

Blood Adv. 2016 Nov 22;1(1):21-30. doi: 10.1182/bloodadvances.2016000216. eCollection 2016 Nov 29.

47.

Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis.

Patnaik MM, Lasho TL, Finke CM, Hanson CA, King RL, Ketterling RP, Gangat N, Tefferi A.

Leukemia. 2016 Nov;30(11):2273-2275. doi: 10.1038/leu.2016.216. Epub 2016 Aug 1. No abstract available.

PMID:
27479179
48.

ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis.

Pardanani AD, Lasho TL, Finke C, Zblewski DL, Abdelrahman RA, Wassie EA, Gangat N, Hanson CA, Ketterling RP, Tefferi A.

Br J Haematol. 2016 Nov;175(3):534-536. doi: 10.1111/bjh.13865. Epub 2015 Dec 2. No abstract available.

PMID:
26628266
49.

Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia.

Zahid MF, Barraco D, Lasho TL, Finke C, Ketterling RP, Gangat N, Hanson CA, Tefferi A, Patnaik MM.

Leuk Lymphoma. 2017 Jun;58(6):1488-1493. doi: 10.1080/10428194.2016.1243681. Epub 2016 Oct 14. No abstract available.

PMID:
27739921
50.

DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia.

Patnaik MM, Barraco D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, Gangat N, Tefferi A.

Am J Hematol. 2017 Jan;92(1):56-61. doi: 10.1002/ajh.24581. Epub 2016 Dec 7.

Supplemental Content

Support Center